BidaskClub Lowers Alexion Pharmaceuticals (NASDAQ:ALXN) to Sell

Alexion Pharmaceuticals (NASDAQ:ALXN) was downgraded by equities research analysts at BidaskClub from a “hold” rating to a “sell” rating in a research report issued on Wednesday, BidAskClub reports.

A number of other brokerages have also recently commented on ALXN. ValuEngine raised shares of Alexion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, October 2nd. SunTrust Banks initiated coverage on Alexion Pharmaceuticals in a research report on Tuesday, November 12th. They set a “buy” rating and a $125.00 target price on the stock. Cowen reiterated a “buy” rating and set a $165.00 target price on shares of Alexion Pharmaceuticals in a research report on Wednesday, October 16th. JPMorgan Chase & Co. reiterated a “buy” rating on shares of Alexion Pharmaceuticals in a research report on Sunday. Finally, William Blair reiterated a “buy” rating on shares of Alexion Pharmaceuticals in a research report on Tuesday, January 14th. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating and fifteen have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $154.00.

Shares of ALXN opened at $113.01 on Wednesday. The firm has a market capitalization of $25.07 billion, a P/E ratio of 17.31, a P/E/G ratio of 0.79 and a beta of 1.64. Alexion Pharmaceuticals has a 12-month low of $94.59 and a 12-month high of $141.86. The company has a current ratio of 3.98, a quick ratio of 3.45 and a debt-to-equity ratio of 0.25. The firm has a fifty day moving average price of $110.42 and a 200-day moving average price of $109.68.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings data on Wednesday, October 23rd. The biopharmaceutical company reported $2.79 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.47 by $0.32. The firm had revenue of $1.26 billion for the quarter, compared to the consensus estimate of $1.24 billion. Alexion Pharmaceuticals had a net margin of 31.05% and a return on equity of 21.21%. The company’s revenue for the quarter was up 23.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.02 earnings per share. Analysts predict that Alexion Pharmaceuticals will post 9.49 earnings per share for the current year.

Several large investors have recently made changes to their positions in the company. Redmile Group LLC purchased a new position in Alexion Pharmaceuticals in the 3rd quarter valued at $113,826,000. Worldquant Millennium Advisors LLC lifted its holdings in Alexion Pharmaceuticals by 429.2% in the 3rd quarter. Worldquant Millennium Advisors LLC now owns 504,514 shares of the biopharmaceutical company’s stock valued at $49,412,000 after purchasing an additional 409,180 shares in the last quarter. Man Group plc lifted its holdings in Alexion Pharmaceuticals by 347.3% in the 3rd quarter. Man Group plc now owns 513,104 shares of the biopharmaceutical company’s stock valued at $50,254,000 after purchasing an additional 398,394 shares in the last quarter. Point72 Asset Management L.P. lifted its holdings in Alexion Pharmaceuticals by 855.4% in the 3rd quarter. Point72 Asset Management L.P. now owns 419,241 shares of the biopharmaceutical company’s stock valued at $41,060,000 after purchasing an additional 375,359 shares in the last quarter. Finally, Krensavage Asset Management LLC purchased a new position in Alexion Pharmaceuticals in the 3rd quarter valued at $24,975,000. Hedge funds and other institutional investors own 91.57% of the company’s stock.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.

Recommended Story: What sectors are represented in the FTSE 100 index?

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.